SMMT Stock — Price, Charts & Analysis
Summit Therapeutics Inc. Stock Fundamentals & Technical Report
Summit Therapeutics Inc. (SMMT) is reviewed here as a complete stock research report for the NasdaqGM market, bringing the core signals into one place: today's price action, valuation, earnings power, balance-sheet quality, cash flow, dividends, ownership, analyst expectations, RSI, support, resistance, moving averages, and technical momentum. The report is built from the data available on Worldtickers and keeps the company name front and center while preserving the ticker for quick market lookup.
Summit Therapeutics Inc. Fundamental Analysis
Summit Therapeutics Inc. Valuation Snapshot
What is the P/E ratio of Summit Therapeutics Inc.?
Summit Therapeutics Inc. (SMMT) has no trailing P/E shown and a forward P/E of -10.33x. This places SMMT in not enough valuation data territory based on the valuation data currently available on Worldtickers.
Is Summit Therapeutics Inc. overvalued or undervalued?
SMMT trades with -10.33x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether SMMT looks overvalued or undervalued.
What is a good P/E ratio for Summit Therapeutics Inc.?
SMMT's P/E of -10.33x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.
What is the EPS of Summit Therapeutics Inc.?
SMMT's trailing EPS is -$1.11 and forward EPS is -$1.20.
What does EPS mean for Summit Therapeutics Inc. investors?
EPS, or earnings per share, shows how much profit Summit Therapeutics Inc. generated for each share. SMMT's trailing EPS is -$1.11, and investors usually prefer EPS that is positive and growing over time.
What is the market cap of Summit Therapeutics Inc.?
Summit Therapeutics Inc. has a market cap of $9.92B, making SMMT a mid-cap stock based on the current market value shown on Worldtickers.
What is Summit Therapeutics Inc.'s stock price today?
SMMT's latest stock price on Worldtickers is $12.43. The latest move is -$0.68 or -5.19%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.
What is Summit Therapeutics Inc.'s stock quote?
SMMT's quote includes a latest price of $12.43. The market open is $13.01. Previous close is $13.11. The intraday range is $12.29 to $13.02.
Why is Summit Therapeutics Inc. stock up or down today?
SMMT is down in the latest quote, with a move of -$0.68 or -5.19%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.
Summit Therapeutics Inc. Business Fundamentals
Is Summit Therapeutics Inc. profitable?
No, SMMT does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -$856.09M.
What is Summit Therapeutics Inc.'s profit margin?
Gross margin is 0.00%. Margins show how efficiently Summit Therapeutics Inc. turns revenue into profit.
What is Summit Therapeutics Inc.'s debt?
Summit Therapeutics Inc. carries $20.38M and holds $690.68M in cash.
Does Summit Therapeutics Inc. have enough cash?
SMMT holds $690.68M on its balance sheet.
What is Summit Therapeutics Inc.'s book value?
SMMT's book value per share is $0.79.
Summit Therapeutics Inc. Ownership Signals
Who owns Summit Therapeutics Inc. stock?
Institutions hold 17.36% of SMMT shares. Insiders hold 80.89% of shares. Ownership mix helps investors understand how much of Summit Therapeutics Inc. is held by professional investors and company insiders.
How many shares of Summit Therapeutics Inc. are outstanding?
SMMT has 797.75M shares outstanding. Float shares are 152.28M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.
Should I follow Summit Therapeutics Inc. insider trades?
Insider activity can be useful context for SMMT, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.
Summit Therapeutics Inc. Earnings Outlook
What to expect from Summit Therapeutics Inc. earnings?
Forward EPS for SMMT is -$1.20. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.
What is Summit Therapeutics Inc.'s earnings history?
SMMT's trailing EPS is -$1.11. Forward EPS is -$1.20. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.
Summit Therapeutics Inc. Investment View
Is Summit Therapeutics Inc. better than Healthcare average?
SMMT is in the Healthcare sector. Its earnings multiple is -10.33x. Compare these figures with sector peers before deciding whether Summit Therapeutics Inc. is stronger or weaker than average.
Should I invest in Summit Therapeutics Inc. now?
SMMT trades at $12.43. The stock trades at -10.33x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Summit Therapeutics Inc.'s fundamentals.
What are the risks of buying Summit Therapeutics Inc.?
SMMT risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is -1.24, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.
How does Summit Therapeutics Inc. compare to its competitors?
SMMT should be compared with companies in Biotechnology. Its earnings multiple is -10.33x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.
Summit Therapeutics Inc. Company Profile
What does Summit Therapeutics Inc. do?
Summit Therapeutics Inc. (SMMT) operates in Healthcare, specifically Biotechnology. Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patien
What exchange does Summit Therapeutics Inc. trade on?
SMMT trades on NasdaqGM. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.
What currency is Summit Therapeutics Inc. stock priced in?
SMMT stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.
What is Summit Therapeutics Inc.'s official website?
Summit Therapeutics Inc.'s official website listed on Worldtickers is www.smmttx.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.
How many employees does Summit Therapeutics Inc. have?
Summit Therapeutics Inc. employs about 265 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.
Where is Summit Therapeutics Inc. headquartered?
Summit Therapeutics Inc. is headquartered in Miami, FL, United States. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.
What sector is Summit Therapeutics Inc. in?
SMMT is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.
Summit Therapeutics Inc. Technical Analysis
What is Summit Therapeutics Inc.'s 52-week high and low?
SMMT has traded between $12.07 and $30.05 over the past 52 weeks. At $12.43, it is 58.64% below the high and 2.98% above the low. The 52-week range helps gauge long-term price momentum.
Is Summit Therapeutics Inc. in an uptrend or downtrend?
SMMT is below both its 50-day and 200-day moving averages, which is a common downtrend signal. Its 50-day moving average is $14.09 and its 200-day moving average is $16.64.
What is Summit Therapeutics Inc.'s RSI?
SMMT's RSI is 39.05. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.
What is Summit Therapeutics Inc.'s RSI today?
SMMT's latest RSI reading is 39.05, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.
What are Summit Therapeutics Inc.'s support and resistance levels?
Key support for SMMT is near $12.07. Key resistance is near $15.75. Breaks above resistance or below support can change the short-term technical setup.
What is the support level for Summit Therapeutics Inc.?
SMMT's nearest reported support level is $12.07. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.
What is the resistance level for Summit Therapeutics Inc.?
SMMT's nearest reported resistance level is $15.75. A breakout above resistance can improve momentum, especially when volume confirms the move.
What is Summit Therapeutics Inc.'s average daily volume?
SMMT trades about 5.33M shares daily on average. The latest displayed volume is 6.57M shares. Volume helps show liquidity and whether trading interest is unusually high or low.
What is Summit Therapeutics Inc.'s MACD?
SMMT's MACD is -0.08, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.
Should I buy Summit Therapeutics Inc. based on technical analysis?
SMMT is below both its 50-day and 200-day moving averages, which is a common downtrend signal. RSI is 39.05 (neutral). MACD is bearish. Nearest support is around $12.07. Resistance is around $15.75. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.
Where is Summit Therapeutics Inc. versus its 20-day, 50-day, and 200-day moving averages?
MA20 is $13.49 (-7.87% from price). MA50 is $14.09 (-11.75% from price). MA200 is $16.64 (-25.28% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.
What is Summit Therapeutics Inc.'s EMA signal?
The server report currently confirms daily moving-average levels rather than a separate EMA-only value. SMMT's MA20 is $13.49. MA50 is $14.09. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.
What are Summit Therapeutics Inc.'s pivot, support, and resistance levels?
SMMT's pivot is near $13.14. Support is near $12.07. Resistance is near $15.75. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.
What are the next support and resistance zones for Summit Therapeutics Inc.?
The next upper resistance zone is near $13.72. These levels help define risk and possible follow-through zones after a breakout or breakdown.
What do Bollinger Bands show for Summit Therapeutics Inc.?
SMMT's Bollinger range is roughly $11.98 to $15.01. Band width is near 22.45%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.
What is Summit Therapeutics Inc.'s ATR volatility?
SMMT's ATR-based typical daily range is about 6.70%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.
Does volume confirm Summit Therapeutics Inc.'s move?
Latest volume is 6.57M shares. Average volume is about 5.33M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.
What is Summit Therapeutics Inc.'s all-time high and low?
SMMT's all-time high shown on Worldtickers is $36.91. Its all-time low is $0.66. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.
What is Summit Therapeutics Inc.'s beta?
SMMT has a beta of -1.24, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.
AI Market Desk
Free plan